6533b820fe1ef96bd1279aa7
RESEARCH PRODUCT
Fluconazole concentrations in pulmonary tissue and pericardial fluid
C. M. Rieder-nelissenR. A. YeatesJ. HasseE. Sarnowsubject
Microbiology (medical)Antifungal AgentsMetabolic Clearance Ratemedicine.medical_treatmentTriazoleBiological AvailabilityPharmacologyPericardial Effusionchemistry.chemical_compoundPharmacokineticsCricetinaemedicineAnimalsHumansPericardiumInfusions IntravenousFluconazoleLungMycosisChemotherapyLungbusiness.industryPericardial fluidGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structurechemistryAnesthesiabusinessFluconazolemedicine.drugdescription
In order to investigate the clinical efficacy of the triazole antifungal agent fluconazole (FCA) in the treatment of pulmonary mycosis, in the present study the concentrations of fluconazole in human pulmonary tissue, pericardial fluid and serum were determined at 1, 2, 12 and 13 h after intravenous administration of fluconazole 200 mg. The mean FCA concentrations in the serum were 4.04 mg/l (1 h), 3.82 mg/l (2 h), 2.35 mg/l (12 h) and 2.13 mg/l (13 h). The respective FCA levels in the pulmonary tissue were 4.64 mg/kg, 4.54 mg/kg; 3.50 mg/kg and 3.40 mg/kg and the concentrations in the pericardial fluid were 3.86 mg/l, 3.57 mg/l, 2.35 mg/l and 2.13 mg/l. The FCA concentrations in the pulmonary tissue that were statistically significant higher than the serum concentrations were found at 2 h, 12 h and 13 h after intravenous administration (p<0.05).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1997-05-01 | Infection |